VisionGate, Inc. today announced that it presented five abstracts describing its Cell-CT™ system for 3D cellular imaging

VisionGate, Inc. presented abstracts describing its Cell-CT system and the Lung Cell Evaluation Device test (LuCED), for early detection of lung cancer, at the 13th World Conference on Lung Cancer, held in San Francisco between July 31 and August 4.

more August 24 2010

VisionGate receives $3 million in government grants

VisionGate has been officially awarded a three-year, $2.62 million grant from NIH as part of an initiative called Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Program.

more June 18 2010

Arizona State University’s Biodesign Institute will acquire the first commercially available Cell-CT™ imaging platform from VisionGate, Inc.

February 26, 2009

Tempe, AZ – In an effort to advance knowledge of human cell biology to improve human health, Arizona State University’s Biodesign Institute will acquire the first commercially available Cell-CT imaging platform from VisionGate, Inc., a Seattle-based private company.

The acquisition places the Biodesign Institute at the forefront of a new generation of medical imaging technologies. The Cell-CT is a sophisticated optical instrument that employs patented computed tomographic (CT) scanning methods to generate high-resolution three-dimensional images of individual cells, allowing precise measurement of cellular anatomy and molecular markers important for understanding and identifying the earliest stages of disease.

“We will use this breakthrough capability to further our research in understanding, predicting and diagnosing cell function or dysfunction at the level of a single cell,” said Deirdre Meldrum, director of the institute’s Center for Ecogenomics and dean of ASU’s Ira A. Fulton School of Engineering. “The Cell-CT uniquely provides a new way to investigate cellular features with the added ability to view designated segments of cells in high resolution 3-D, allowing us a better view into disease-causing processes. ”

Thomas Neumann, M.D., VisionGate’s vice president for medical science, said the sale of the company’s first Cell-CT platform is a significant step for the company. “We are encouraged that the scientists at the Biodesign Institute will be using our novel 3-D cellular imaging technology for their groundbreaking research on single cell biology,” he said. “VisionGate plans to continue developing the Cell-CT system for clinical use in the early detection of lung cancer, and the agreement announced today is expected to provide valuable contributions to the institute’s personalized medicine initiatives.”

VisionGate will install the Cell-CT instrument at the Biodesign Institute’s Center for Ecogenomics in the first quarter of 2009. The agreement includes standard provision for the sale of research instruments, including a short acceptance period following delivery.

About the Biodesign Institute at Arizona State University
The goal of the Biodesign Institute is to improve human health and quality of life through use-inspired biosystems research and effective multidisciplinary partnerships. The Center for Ecogenomics is developing tools, sensors and systems to detect and analyze differences between healthy and diseased cells as well as to identify genetic traits that enable certain microorganisms to adapt to harsh environments. For more information visit:

To learn more about Fulton School of Engineering Dean Deirdre Meldrum’s research, go to:

About VisionGate, Inc.
VisionGate, a privately held corporation in Washington State, has developed the proprietary 3-D cell image analysis platform, the Cell-CT, based on the company’s broadly patented technology. The Cell-CT is capable of generating high-resolution 3-D information from intact cells for automated analysis of biomarkers and pathology. For more information visit VisionGate’s website at:


more February 26 2009

VisionGate and Seattle Cancer Care Alliance join forces to explore new technology for evaluating lung cancer risk

Seattle, WA, December 17, 2008 – VisionGate, Inc. (a local privately held biomed/biotech company) today announced its collaboration with the Seattle Cancer Care Alliance (SCCA) for the clinical development of a new lung cancer risk assessment test targeting current and former smokers. The test utilizes VisionGate’s Cell-CT platform that generates high-resolution threedimensional images of cells isolated from patient sputum (phlegm) to precisely measure cellular features and molecular markers. The collaboration will help to develop potential markers for early signs of cancer and pre-cancerous conditions.

When the lungs are exposed to carcinogenic insult, such as long-term smoking, the cells that form the inner lining of the airways undergo characteristic changes that correlate with increased risk of developing lung cancer. Sputum contains high numbers of these lung cells, and the Cell-CT  can automatically detect the appropriate cells and measure cellular features in 3D with unprecedented clarity. It is the goal of the study to investigate the generation of a lung cell evaluation score that potentially could be used by the physician as a patient management guide.

There are approximately 100 million current and former smokers in the U.S. alone, a risk groupwherein 80-90% of all lung cancer cases occur. Published studies show that early detection dramatically increases the chance of surviving lung cancer. Unfortunately, most lung cancers are detected in the late stage when symptoms have already arisen and treatment options are limited. Currently, there is no widely practiced screening or risk-assessment method for lung cancer.

Dr. Jason Chien, M.D., M.S., a pulmonary and critical-care specialist, directs the Lung Cancer Early Detection and Prevention clinic at the SCCA–a multidisciplinary clinic for current and former smokers to help assess the condition of patient’s lungs and encourage smoking cessation. The clinic was launched in January 2008 under the auspices of the Fred Hutchinson Cancer Research Center. The patient’s diagnostic evaluation includes an assessment of medical history, a lung function test, and, if clinically appropriate, a low-dose CT scan of the lungs to localize a potential lung tumor. Now under investigation is whether  VisionGate’s technology  for sputum analysis would provide an improved triage of patients who should receive the CT scan. In the initial phase of the collaboration with VisionGate, through a clinical study protocol that has been approved by the SCCA Institutional Review Board,  patients at Dr. Chien’s clinic can opt to provide their sputum sample for further refining and testing of the Cell-CT platform.

About Seattle Cancer Care Alliance

Seattle Cancer Care Alliance, established in 1998, unites the adult and pediatric cancer-care services of Fred Hutchinson Cancer Research Center, UW Medicine and Children’s Hospital and Regional Medical Center. A major focus of SCCA is to speed the transfer of new diagnostic and treatment techniques from the research setting to the patient bedside while providing premier, patient-focused cancer care. Patients who come to SCCA receive the latest research-based cancer therapies as well as cutting-edge treatments for a number of non-malignant diseases under development by its partner organizations. SCCA has three clinical-care sites: an outpatient clinic on the Fred Hutchinson campus, a pediatric-inpatient unit at Children’s and an adult-inpatient unit at UW Medical Center. For more information about SCCA, visit

About VisionGate, Inc.

VisionGate, a privately held corporation in Washington State, has developed the proprietary 3D cell image analysis platform, the Cell-CT, based on the company’s broadly patented technology. The Cell-CT is capable of generating high-resolution 3D information from intact cells for automated analysis of cancer biomarkers.

visit VisionGate’s website at:

more December 17 2008

Peer-reviewed publication in Pattern Recognition demonstrates superiority of VisionGate’s Cell-CT™ patented 3D cell imaging platform

Seattle, WA, September 29, 2008 – VisionGate, a privately held biomed/biotech company, today announced the publisher’s notification of acceptance of a study comparing classification efficacy based on 3D images of cells compared to conventional 2D microscopy of the same cells.

VisionGate’s study, authored by Michael G. Meyer, et al., and entitled “Automated cell analysis in 2D and 3D: A comparative study” is scheduled for publication in early 2009 in Volume 42 (pages 141-146) of Pattern Recognition, the prestigious journal devoted to leading research in pattern recognition, published by Elsevier. The journal article is now available online at:

VisionGate has demonstrated that 3D imaging of cells is inherently more information rich than the 2D microscope counterpart, and this advantage significantly improves the performance of automated cell disease-state recognition. The publication provides experimental proof of the important advantage of 3D imaging of cells in a study involving the computerized classification of lung adenocarcinoma cell nuclei vs. normal lung  cell nuclei. Particular care was taken to perform 3D and 2D classification on the exact same set of cells, thus avoiding potential sources of bias that might otherwise confound the comparison of 3D and 2D cell imaging. The advantage of 3D over 2D is shown to be statistically significant and increases as higher levels of sensitivity and specificity are demanded.

Dr. Alan Nelson, VisionGate’s Chairman and CEO said: “We have developed a breakthrough technology, called Cell-CT, to automatically interrogate biological cells in their more natural 3D intact condition and measure their internal biomarker features that may be predictive of disease. As we look first to evaluate cell markers for evidence of lung cancer risk, it is important to establish that the Cell-CT platform, with its high-resolution 3D imaging capability, will provide a quantitative advantage over conventional 2D microscopy. This new publication in Pattern Recognition helps establish the important role of 3D cell biomarker analysis in cancer research.”

About VisionGate, Inc.

VisionGate, a privately held corporation in Washington State, has developed an innovative 3D cell imaging and characterization platform,  the Cell-CT, based on the company’s broadly patented technology. The Cell-CT is capable of generating high resolution 3D information from intact cells for automated analysis of cancer biomarkers. Cells are injected into capillary tubes that rotate, allowing multiple viewing angles to tomographically compute the cell’s internal 3D structure; thus enabling spatially defined densitometry of labeled molecular species.

more September 29 2008

Swedish Cancer Institute Taking Part in Development of Cell-CT™ Platform for Lung Cancer Risk Assessment

Swedish Cancer Institute Taking Part in Clinical Trial of Sputum Test for Early Detection of Lung Cancer

SEATTLE, May, 2, 2008Swedish Cancer Institute announced today it is collaborating with VisionGate, Inc. – a privately held biomed/biotech company based in Seattle – to provide samples from lung-cancer patients for further development of VisionGate’s Cell-CT platform, an automated cell analysis instrument that employs patented 3D computed tomographic scanning of intact biological cells to screen patients for early indications of cancer risk. The company’s LuCED (Lung Cell Evaluation Device) test, which is analyzed on the platform, uses a person’s sputum for non-invasive early detection of lung cancer.

Lung cancer is the number one cancer killer worldwide with more than 162,000 deaths in the United States this year and 500 deaths per day in North America. The World Health Organization (WHO) estimates that the annual incidence of lung cancer now approaches 1,000,000 new cases worldwide. To date, due to the lack of a cost-effective early detection method, lung cancer is usually diagnosed late when treatment options are less effective. “Our participation in this clinical trial is an example of our dedication to exploring and perfecting the best cancer treatment opportunities available, including the development of screening programs aimed at providing the earliest indication that a patient is at risk,” said Albert B. Einstein Jr., M.D., executive director of the 75-year-old Swedish Cancer Institute.

“We are pleased to be working with VisionGate on this clinical tial,” said Ralph Aye, M.D.thoracic surgeon and principal investigator for the VisionGate study at the Swedish Cancer Institute. “Since we are committed to exploring leading-edge technologies designed to improve patient outcomes in a cost-effective manner, VisionGate’s LuCED test definitely fits that profile.”

Alan Nelson, Ph.D., VisionGate’s Chairman and CEO, said, “The highly accomplished team at Swedish, and their leadership in the field of cancer research and patient management, will no doubt provide VisionGate with important guidance toward the successful implementation of the LuCED test as a new tool in lung cancer screening. We are honored to be working with Dr. Aye and the Swedish Cancer Institute in this pivotal research program.”

Early detection can dramatically increase the chance of surviving lung cancer, but most lung cancers are detected in later stages after symptoms occur and therapies are less likely to be successful. To date, no widely practiced screening method for lung cancer is in use, although there are approximately 90 million current and former smokers in the United States alone, a risk group in which 80 percent to 90 percent of all lung cancer cases will occur.

For that reason, the Swedish Cancer Institute has entered into this clinical-trial collaboration with VisionGate, which is dedicated to the early detection of lung cancer. VisionGate has developed the Cell-CT platform, a technology that allows automated screening of patient sputum for cells obtained with the LuCED sample collection kit. The cells are imaged in 3D, which allows for the measurement of cellular features that are indicative of cancer. The cell analysis of patient sputum is then translated into a risk score that can help guide a physician’s further diagnostic workup, such as low-dose CT Scan or bronchoscopy.

The Swedish Cancer Institute is participating in VisionGate’s efforts to develop the LuCED screening test for lung cancer by providing cell specimens from cancer patients, which are used for instrument training and testing.

VisionGate’s other participant sites in this clinical trial include the Weill Cornell Medical College in New York, NY; the University of Toronto in Ontario, Canada; and the University of Navarra in Pamplona, Spain. The Swedish Cancer Institute is VisionGate’s first collaborator in the Pacific Northwest.

About the Swedish Cancer Institute

The Swedish Cancer Institute (SCI) opened in 1932 as the first dedicated cancer-care center west of the Mississippi. Today, SCI has a presence on all three of Swedish’s hospital campuses – First Hill, Cherry Hill and Ballard – as well as in East King County through a new medical oncology clinic in Bellevue. A true multidisciplinary program, SCI offers a wide range of advanced cancer-treatment options in chemotherapy, radiation therapy and surgery – backed by extensive diagnostic capabilities, patient education and support-group services. SCI-managed radiation-therapy services are also offered at Stevens Hospital in Edmonds, Highline Community Hospital in Burien, and Northwest Hospital in North Seattle. The SCI clinical-research arm encompasses industry-sponsored and cooperative group therapeutic trials, cancer screening and prevention trials, and investigator-initiated trials. Breast-cancer screening and diagnostics are available through the Swedish Breast Care Centers and mobile mammography units. SCI patients benefit from an integrated approach to care which takes into account a person’s physical well-being and emotional/spiritual needs, too. From prevention and early detection, to state-of-the-art treatments and complementary therapies, to supportive and palliative care, SCI meets the individual needs of each patient. For more information, visit

About VisionGate, Inc.

VisionGate, Inc. has developed the Cell-CT platform, which is an innovative, cell-analysis system based on the company’s broadly patented technologies. The Cell-CT platform generates high-resolution 3D images of intact cells and their internal structures for automated analysis of features that reflect the disease state of cells, including pre-cancer and cancer conditions. VisionGate’s Cell-CT platform with associated reagents and disposables is entering clinical studies on human subjects in the United States, Canada and Europe to further develop the company’s proprietary LuCED test for early detection of lung cancer. VisionGate, Inc. is a privately held company based in Seattle, Wash. For more information, visit

more May 1 2008

Copyright 2019 - VisionGate, Inc.